AIM: £2.81 (-0.06) | Nasdaq: $17.80 (-0.05)
新闻档案

通过选择所需的新闻类型，可以获得最新的公告或演示文稿。

请使用 「新闻主题」进一步挑选公告类别。
 

所有公告的全文可以PDF文件的形式下载。为方便起见，某些公告的部分或全部文字内容以网页的方式呈现。如存有任何不一致之处，请以PDF版本为准。

新闻类型
演示文稿
监管信息公告
新闻主题
创新平台
商业平台
监管通知
集团
1
2
找到相关结果： 88
演示文稿, 科学出版物 | 2020-03-13

ENETS 2020 : 索凡替尼用于中国晚期非胰腺神经内分泌瘤患者的安全性和特殊不良事件：SANET-ep研究数据分析
>> 相关报道 The previously reported SANET-ep trial (clinicaltrials.gov identifier NCT02588170) demonstrated that surufatinib significantly improves progression-free survival (“PFS”) in patients with advanced extrapancreatic (non-panc
阅读更多
下载海报
事件, 公司介绍, 演示文稿 | 2020-03-03

2019全年财务业绩
通告发布： 8pm HKT (12 noon GMT / 7am EST)  >> 查看通告 简报会网络直播及电话会议：9pm HKT (1pm GMT / 8am EST) >> 点击收看网络直播回放 To participate by phone, please use o
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2020-02-06

《柳叶刀·肿瘤学》奥希替尼与沃利替尼用于EGFR突变、MET扩增的非小细胞肺癌
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Lecia V Sequist;
阅读更多
公司介绍, 演示文稿 | 2020-01-20

公司介绍
下载演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2020-01-15

第38届摩根大通医疗健康年会
地址：Westin St. Francis Hotel, San Francisco, CA 日期：2020年1月15日（星期三） 时间：1pm PST（4pm EST/9pm BST/北京时间16日凌晨5点） 录音：请下载附带的演示文稿 [audio mp3="http://www.c
阅读更多
下载演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2019-11-13

德意志银行美国存托股份虚拟投资者会议 (dbVIC)
在线虚拟投资者会议 时间：09:30 pm HKT (01:30 pm GMT/08:30 am EST) >> 点击收看网络直播回放  
阅读更多
下载演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2019-09-30

ESMO 2019 : 索凡替尼最新数据与进展
Press release released:  September 29, 2019 (Sun)  >> See press release here Presentation webcast & call:  September 30, 2019 (Mon) 2pm CEST (1pm BST/8am EDT/8pm HKT) >> Click here for the webcast replay
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2019-09-29

ESMO 2019: 索凡替尼用于治疗高分化的晚期非胰腺神经内分泌瘤患者的疗效和安全性
标题： 索凡替尼用于治疗高分化的晚期非胰腺神经内分泌瘤患者的疗效和安全性：随机化的III期临床试验（SANET-ep）结果 报告人： 中国人民解放军总医院第五医学中心 消化肿瘤科
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2019-09-21

CSCO 2019: FRESCO研究中手足皮肤反应的发生情况及与疗效的关系
报告2 FRESCO 研究中手足皮肤反应的发生情况及与疗效的关系 报告人： 白玉贤，哈尔滨医科大学附属肿瘤医院 其他作者： 李进 ，秦叔逵 ，徐瑞华，沈琳，徐建明，邓艳红，杨
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2019-09-19

CSCO 2019 : 呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析
报告 呋喹替尼三线治疗中国转移性结直肠癌的III 期临床研究（FRESCO）中的肝转移亚组分析 报告人： 秦叔逵，东部战区总医院（原八一医院） 其他作者： 李进，徐瑞华，沈琳
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2019-09-09

WCLC 2019: 呋喹替尼治疗晚期非小细胞肺癌（FALUCA）III期试验
MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)   Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 - The Adequate MTarget
阅读更多
Download Presentation (PDF)
事件, 公司介绍, 演示文稿 | 2019-09-09

第26届中信里昂投资者论坛
地址：香港君悦酒店
下载演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2019-07-30

2019年中期业绩简报
Announcement released: 7am BST (2pm HKT/2am EDT)  >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9pm HKT)
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2019-06-01

《Clinical Cancer Research》：索凡替尼在高分化神经内分泌瘤的使用
Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, 3 single-arm, open-label, phase Ib/II trial Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao
阅读更多
事件, 公司介绍, 演示文稿 | 2019-05-20

摩根士丹利中国峰会2019
地址：北京瑰丽大酒店
下载英文版演示文稿 (PDF)下载中文版演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2019-05-08

摩根大通全球中国峰会2019
地址：北京国贸大酒店
下载英文版演示文稿 (PDF)下载中文版演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2019-03-11

2018全年财务业绩
Announcement released: 7am BST (3pm HKT / 3am EDT) >> See announcement here Presentation webcast & call: 9am BST (5pm HKT / 5am EDT) >> Click here for the webcast US conference call: 9am EDT (1pm BST/9pm HKT
阅读更多
下载演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2019-01-07

第37届摩根大通医疗健康年会
地址： Westin St. Francis Hotel, San Francisco, CA 日期： 2019年1月9日（星期三） 时间： 9:30am PST (12:30pm EST/5:30pm BST) 录音： 请下载附带的演示文稿 [audio mp3="http://www.chi-med.com/wp-co
阅读更多
下载演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2018-07-27

2018年中期业绩简报
  Announcement released: 7am BST (2pm HKT/2am EDT)  >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2018-06-26

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;
阅读更多
演示文稿, 科学出版物 | 2018-06-04

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F
阅读更多
View Poster
演示文稿, 科学出版物 | 2018-06-04

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO
Presenter:     Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y
阅读更多
演示文稿, 科学出版物 | 2018-04-17

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib
4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets
阅读更多
View Poster
演示文稿, 科学出版物 | 2018-03-23

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans
Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa
阅读更多
事件, 公司介绍, 演示文稿 | 2018-03-12

2017全年财务业绩
Announcement released: 7am BST (3pm HKT/3am EDT) » See announcement here Presentation webcast & call: 9am BST (5pm HKT/5am EDT) » Click here for a video of the webcast US conference call: 9am EDT (1pm BST/9pm HKT)
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2018-03-12

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC
 Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung
阅读更多
演示文稿, 科学出版物 | 2018-02-24

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
阅读更多
演示文稿, 科学出版物 | 2018-02-20

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can
阅读更多
演示文稿, 科学出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC
OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han
阅读更多
演示文稿, 科学出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC
OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T
阅读更多
演示文稿, 科学出版物 | 2017-10-15

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC
JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA
阅读更多
演示文稿, 科学出版物 | 2017-09-28

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer
Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,
阅读更多
演示文稿, 科学出版物 | 2017-09-28

CSCO 2017: Theliatinib Phase I Results
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif
阅读更多
演示文稿, 科学出版物 | 2017-09-27

CSCO 2017: FRESCO In-Depth Analysis
In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen
阅读更多
演示文稿, 科学出版物 | 2017-09-27

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer
Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi,  Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei
阅读更多
事件, 公司介绍, 演示文稿 | 2017-09-16

The Royal Society of Medicine 15th Medical Innovations Summit
The Royal Society of Medicine, London, UK Please visit rsm.ac.uk for more information. A video recording of the 20-minute presentation is available. RSM video link Note: there is a 25-second audio error at 2:55.  
阅读更多
下载演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2017-07-31

2017年中期业绩简报
Announcement released: 7am BST (2am EDT, 2pm HKT) » See announcement here Presentation webcast & call: 9am BST (4pm HKT) » click here for a video of the webcast US conference call: 9am EDT (2pm BST) » To parti
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2017-06-23

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC
Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur
阅读更多
事件, 公司介绍, 演示文稿 | 2017-06-21

Bernstein Conference: China Oncology Day
Mandarin Oriental, Hong Kong
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2017-06-05

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)
A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol
阅读更多
演示文稿, 科学出版物 | 2017-06-05

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti
阅读更多
演示文稿, 科学出版物 | 2017-04-04

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases
Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,
阅读更多
演示文稿, 科学出版物 | 2017-04-03

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models
Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,
阅读更多
事件, 公司介绍, 演示文稿 | 2017-03-30

R&D Briefing for Investors 2017
Introduction The Future of Targeted Cancer Therapy In Lung Cancer Post-POC Portfolio Pre-POC Portfolio Research Strategy Transforming into a Fully Integrated Global Biopharma Wed. Mar 29, 9:30am - South Place Hotel, London, UK » Cli
阅读更多
下载演示文稿 (PDF)
事件, 公司介绍, 演示文稿 | 2017-03-13

2016全年财务业绩
Announcement released: 7am GMT » See announcement here Webcast presentation & conf call: 9am GMT (5pm HKT) » click here for a video of the webcast (available for six months) » To participate by phone, please us
阅读更多
下载演示文稿 (PDF)
演示文稿, 科学出版物 | 2017-03-09

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su Summary: The current Phase
阅读更多
演示文稿, 科学出版物 | 2017-01-20

ASCO GI 2017: Fruquintinib in Combination with Paclitaxel in 2L Gastric Cancer
A Phase I/II Trial of Fruquintinib in Combination with Paclitaxel for Second-line Treatment in Patients with Advanced Gastric Cancer Ruihua Xu, Dongsheng Zhang, Lin Shen, Jin Li, Jing Huang, Yang Zhang, Jifang Gong, Weijian Guo, Songhua Fan, Ke Li,
阅读更多
演示文稿, 科学出版物 | 2017-01-19

Journal of Hematology & Oncology: fruquintinib Phase Ib & Phase II in colorectal cancer
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study   Authors: Rui-Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin She
阅读更多
演示文稿, 科学出版物 | 2016-12-06

WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC
A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer  (NCT02590965) Shun Lu1, Jianhua Chang2, XiaoQing Liu3, Jianhua Shi4, You Lu5, Wei Li6, Jinji Yang7, Jianying Zhou8, Jie Wa
阅读更多
演示文稿, 科学出版物 | 2016-12-06

ASH 2016: Syk Inhibitor HMPL-523 Anti-tumor Activity in vitro and in vivo
HMPL-523, a Novel SYK Inhibitor, Showed Anti-tumor Activities in Vitro and in Vivo Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Yongxin Ren, Weiguo Qing and We
阅读更多
1
2